All the news Showing 10 of 31 articles from: Deciding when and how to treat HCVGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Hepatitis C treatment can be shortened in 50 percent of patients, study finds Eurekalert Inf Dis / 12 November 2018 BIDMC researchers develop decision-making tool to benefit patients with HCV Eurekalert Medicine & Health / 20 June 2018 EASL issues new hepatitis C treatment recommendations for all genotypes Liz Highleyman / 26 September 2016 The European Association for the Study of the Liver (EASL) released its latest recommendations on treatment of hepatitis C at a special meeting last Thursday in Paris. The updated guidelines now include highly ... HCV treatment is effective and may work as prevention for people who inject drugs Liz Highleyman / 19 September 2016 Hepatitis C treatment for people who inject drugs is as safe and effective as it is for non-drug-users – with cure rates exceeding 90% – and treating enough people in this population could ... Hepatitis C Guidance Underscores the Importance of Treating HCV Infection: Panel Recommends Direct-Acting Drugs for Nearly All Patients with Chronic Hepatitis C IDSA / 27 October 2015 US study provides 'real world' evidence about which patients with hepatitis C should be prioritised for therapy Michael Carter / 19 October 2015 For patients with hepatitis C virus (HCV) mono-infection, baseline fibrosis stage is strongly predictive of the medium-term risk of serious liver disease and death, investigators from the United States report in the ... New HCV NS5A inhibitor EDP-239 looks good in early studies, more evidence supports early hepatitis C treatment Keith Alcorn / 07 October 2015 A new hepatitis C virus (HCV) NS5A inhibitor being developed by Enanta – EDP-239 – was well-tolerated and demonstrated promising antiviral activity against genotype 1 HCV in a single-dose monotherapy study presented at ... Liver function and survival improve after treatment with Viekirax + Exviera regimen Liz Highleyman / 27 June 2015 People with hepatitis C who were treated with AbbVie's Viekirax plus Exviera or '3D' regimen saw improvements in liver function biomarkers, had better quality of life and had increased survival compared to ... Hepatitis C: 25 Years Old, and Fading Medscape / 17 June 2015 Shortening hepatitis C treatment to 6 weeks effective but not perfect for easier-to-treat patients Keith Alcorn / 13 May 2015 Shortening hepatitis C treatment to 6 weeks for easier-to-treat patients without cirrhosis does not greatly reduce the efficacy of hepatitis C treatment for people with genotype 1 infection, according to results of a ... ← First123...4Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive